SK Holdings, a holding company that through its subsidiaries, operates refineries, chemicals, telecommunications, oil exploration, and transportation, agreed to invest $200m in Roivant Sciences, a healthcare company focused on applying technology to drug development. “SK Holdings and Roivant share many things in common, including our investment philosophy and our desire to improve upon the status quo by working together. We believe that AI-powered targeted protein degradation will not only improve inefficiencies in the pharmaceutical industry, but also generate significant social impact by tackling unmet medical needs. In addition to this partnership, we look forward to working together to innovate on other aspects of healthcare with a long-term vision,” Dong Hyun Jang, SK Holdings CEO.